Glenoliv 300 Tablet contains Ursodeoxycholic Acid 300 mg, a hydrophilic bile acid used primarily in the management of various hepatobiliary disorders. Ursodeoxycholic Acid acts by reducing the cholesterol content of bile and bile stones, thereby promoting their dissolution and preventing stone formation. It also exerts cytoprotective effects on hepatocytes and cholangiocytes by stabilizing cell membranes and reducing the toxic effects of hydrophobic bile acids. Glenoliv 300 is indicated for the treatment of primary biliary cholangitis, cholesterol gallstones in patients who are not candidates for surgery, and certain cholestatic liver diseases. The medication is typically administered orally, with dosage tailored according to the specific condition and patient response. Common side effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort, though it is generally well tolerated. Caution is advised in patients with biliary obstruction, liver failure, or hypersensitivity to the active ingredient. Regular monitoring of liver function tests is recommended during therapy to assess efficacy and detect potential adverse effects. Glenoliv 300 should be used under medical supervision to ensure optimal therapeutic outcomes and minimize risks.